People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harpoon Therapeutics, Inc. | — | Biotechnology | Series D+ | $220.3M | $1.4B | 2018 |
| Caribou Biosciences, Inc. | — | Biotechnology | Series D+ | $141.0M | $3.8B | 2021 |
Natalie R. Sacks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Natalie R. Sacks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Weisskoff | 1 | 12 |
| Alan Colowick | 1 | 7 |
| Jenny Rooke | 1 | 5 |
| Mark Chin | 1 | 4 |
| Gerald McMahon | 1 | 3 |
| Rodolphe Barrangou | 1 | 3 |
| Luke Walker | 1 | 3 |
| Mark E. Chin | 1 | 2 |
| Lauren Silvernail | 1 | 2 |
| Joseph Bailes | 1 | 2 |
| Ron R. Hunt | 1 | 2 |
| Andrew May | 1 | 2 |
| Rachel Haurwitz | 1 | 2 |
| Jonathan Drachman | 1 | 2 |
| Barbara G. McClung | 1 | 2 |
| Scott Myers | 1 | 2 |
| Ronald Hunt | 1 | 2 |
| Andrew Robbins | 1 | 2 |
| Philip E. Austin | 1 | 1 |
| Un G. Kwon-Casado | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.